Merck & Co.

The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.

Restricting face-to-face interactions with people will go a long way in limiting the spread of the virus.

Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look.

The primary endpoint was a statistically significant improvement in progression-free survival for the combination versus platinum-based chemotherapy.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.